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Aryl iodides have become widely recognized as versatile synthetic 
intermediates, owing to aromatic iodine’s excellent ability to participate in oxidative 
addition reactions. Iodoarenes readily undergo a variety of synthetic transformations 
including metal catalyzed cross-coupling reactions, diaryliodonium chemistry, 
formation of organometallics through reduction or metal-halogen exchange, as well as 
classical SN2 type chemistry. Because a wide array of transformations are available for 
aryl iodides, organic molecules containing this moiety often serve as vital precursors 
to highly desirable pharmaceuticals. 
This thesis describes a simple and selective two-step approach to the formation 
of aryl iodides. This method proceeds through an easily purified diaryliodonium salt 
intermediate, which is subsequently converted to the corresponding aryl iodide. This 
method is an effective and general process for the selective synthesis of a large variety 
of monoiodinated arenes that are difficult to access by other approaches.  
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CHAPTER ONE 
POSITRON EMISSION TOMOGRAPHY 
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1.1 INTRODUCTION 
1.1.1 Positron Emission Tomography 
Positron Emission Tomography (PET) is a very powerful molecular imaging 
technique that is used to produce a three dimensional image of certain organs within the 
body.1 This in vivo method allows for the non-invasive diagnosis of a wide range of 
diseases, making it a useful tool in biomedical research. Through PET, researchers gain 
valuable insight into vital physiological processes, which allows them to monitor the 
pharmacokinetics and circulation of various drugs throughout the body. In order to 
administer a PET scan, a drug labeled with a short-lived positron-emitting radioisotope is 
prepared and injected into the body. These drugs are commonly referred to as 
radiotracers. Once the radiotracer has become concentrated within the tissues or organs of 
interest and cleared from background tissues, the patient is placed into a device known as 
a scintillation detector (Figure 1.1).  
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Figure 1.1 Diagram of a scintillation detector used in PET 
The radionuclide of the labeled drug undergoes as process known as positive beta 
decay, in which a positron is emitted. This positron travels a short distance, (about 2-5 
mm) which is dependent upon the average kinetic energy of the ejected positron. When 
the positron has lost enough energy to interact with an electron in the nearby tissues, an 
annihilation event consumes both particles and produces a pair of 511 keV gamma rays 
that radiate, at 180° angles, from the annihilation event. This coincident pair of photons is 
then detected by the scintillation detector, which defines a line along which the 
annihilation event occurred. Since the circular detector collects coincident events at many 
angles, a map of the defined lines shows intersection points that pinpoint where, and in 
what tissues, the radiotracer has become concentrated. The resolution of the image scales 
inversely with the distance the positron travels before interacting with an electron in an 
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annihilation event, and therefore radionuclides that emit positrons with low kinetic 
energy yield the highest resolution images.  
 
1.1.2 PET Imaging using Fluorine-18 (18F) 
PET imaging has traditionally used radionuclides with relatively short half-lives, 
such as carbon-11, nitrogen-13, oxygen-15, and fluorine-18. However, there are certain 
considerations (Table 1.1) that must be taken into account when considering which 
radioisotope to use, including the average positron kinetic energy, the specific activity, 
and especially the half-life. 
 
Table 1.1 Positron emitters commonly used in PET. 
 
Isotope Half-life Decay mode Eβ+Avg. (KeV) 
Maximum 
(Average) 
Range in 
Tissue (mm) 
Maximum 
Specific 
Activity 
(GBq/μmol) 
11C 20.39 min β+ (99.8%) 
EC (0.24%) 
385 3.8 (1) 3.4x105 
13N 9.965 min β+ (99.8%) 
EC (0.2%) 
491 5 (1.5) 7.0x105 
18O 122.24 sec β+ (99.9%) 
EC (0.1%) 
735 7.6 (2.7) 3.4x106 
18F 109.77 min β+ (96.73%) 
EC (3.3%) 
242 2.2 (0.3) 6.3x104 
124I 4.1760 days β+ (22.8%) 
EC (11.0%), e- 
188 9.7 (3) 1.2x103 
Nuclear properties of commonly used positron emitting radionuclides used in PET. Data taken from 
Brown and Firestone 1986 and from Brookhaven National Laboratory internet database, BNL 2003 
 
 18F-labeled  imaging agents provide higher resolution images that those afforded 
by tracers labeled with the other radionuclides listed in Table 1.1.  The reason for this is 
that 18F emits a  positron with relatively low kinetic energy, which is associated with an 
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annihilation event closer to the decay event. A short half-life is desirable for most 
diagnostic scans involving small molecule tracers that localize and clear quickly, but the 
synthetic routes used to synthesize many radiotracers preclude all but the most well-
equipped hospitals from using novel PET diagnostic agents.  Generally, a nearby 
cyclotron and an experimental radiochemistry laboratory are required in order to 
synthesize 18F-labeled radiotracers. It is more common for hospitals to purchase standard 
18F-labeled tracers, such as fluorodeoxyglucose (FDG), from commercial 
radiopharmacies. 
Generally, one desires  a radiotracer to have the shortest possible half-life that is 
commensurate with obtaining a quality image. In practice this means that the 
radionuclide half-life must be sufficiently long to allow for synthesis of the radiotracer 
from the radionuclide, administration to the patient, localization in the tissue of interest, 
and clearance from background tissue. Toward these ends, fluorine-18 is the most 
commonly used radionuclide for incorporation into small molecule radiotracers,2 as it can 
be synthesized off-site, incorporated into a radiotracer, and then shipped to diagnostic 
centers while still retaining a useful amount of radioactivity.  In addition, the nuclear 
reaction which produces 18F from H2
18O yields several hundred times the amount of 18F 
needed for a single human PET scan, and synthetic routes exist that give desirable 
radiotracers in high radiochemical yields.3 
Choosing to use 18F as the radiolabel on pharmaceutical provides additional 
benefits to those outlined above.4 The carbon-fluorine bond is one of the strongest in 
organic chemistry, owing to fluorine’s high electronegativity. The dipolar nature of the 
C-F bond induces an electrostatic attraction between carbon and fluorine,5 which shortens 
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and strengthens the bond. Replacing hydrogen atoms with fluorine in pharmaceuticals6 
also lends metabolic stability to the carbon framework, while introducing minimal 
structural perturbations. The small size of the fluorine atom makes it an appropriate 
replacement for hydrogen, thus, singly fluorinated organic compounds often behave very 
similarly to the corresponding hydrocarbon. While replacing hydrogen with fluorine in 
organic compounds changes little in the way of the physical structure of the compound, 
the fluorine is highly electronegative and alters the electronic properties of the 
molecule,7,8 making it a good bioisostere for a Lewis basic hydroxyl group. 
 
 
Figure 1.2 Common 18F and F labeled pharmaceuticals. Figure adapted from reference 90. 
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Because of these advantages, about one fifth of all pharmaceuticals contain at 
least one fluorine atom. Incorporation of fluorine into pharmaceuticals has been reported 
to increase the likelihood of creating a successful drug by a factor of ten9,10 (Figure 1.2). 
Fluorine substituted organic compounds often display increased lipophilicity over their 
corresponding hydrocarbons, which can be a desirable pharmacological property in some 
cases.11 Additionally, replacing hydrogen with fluorine at a site of metabolic oxidation 
may extend the serum half-live of a drug in the body. This is an especially useful strategy 
to protect drugs that are susceptible to cytochrome P-450 catalyzed hydroxylation, a 
catabolic process that accounts for approximately 75% of all drug metabolites.  
Replacement of an aromatic hydrogen with fluorine stabilizes aromatic groups that are 
sensitive to this type of drug metabolism.12-18 
1.1.3 Routes to 18F-labeled Radiotracers 
While 18F is a highly desirable radiolabel, the introduction of 18F into 
pharmaceuticals poses a significant challenge for organic chemists. Elemental fluorine 
and hydrogen fluoride are difficult to handle and require specialized techniques and 
equipment, as they are highly reactive and very dangerous. Fluorine is one of the most 
reactive substances known, due to the strength of the bonds that fluorine forms with most 
other elements and the relative weakness of the fluorine-fluorine bond. 
In order to accomplish the difficult task of fluorination, a variety of methods may 
be used. Electrophilic fluorination is a common method employed, and for this purpose 
elemental fluorine is commonly used in the form [18F]F2. Radioactive fluorine [
18F]F2 
used in electrophilic labeling techniques is generated in a cyclotron. The most common 
nuclear reaction used is 18O(p,n)18F in which the bombardment of [18O]-oxygen produces 
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[18F]F2, although a different, less common, reaction, 
20Ne(d,α)18F uses neon as the 
bombardment target. In the reaction using [18O]-oxygen, a trace amount of F2 gas is 
sometimes added to extract the radioactive [18F]F2, which produces a mixture of  [
18F]F2 
and [
19F]F2 as the final product. This method is called “carrier added.” In practice, only a 
handful of cyclotron facilities in the world are able to produce [18F]F2 on a reliable basis. 
When using elemental fluorine, the fluorine molecule is highly polarized, which 
allows electron-rich or Lewis basic substrates to act as nucleophiles. If this method is 
utilized, the upper limit of the radiochemical yield (RCY) is only 50%, due to the fact 
that 50% of the radioactivity is consumed in the chemical transformation and the other 
50% is lost as the leaving group.2 Electrophilic fluorination with F2 also suffers from low 
specific activity of the final product, because a carrier gas (non-radioactive F2) is added 
in order to extract the [18F]F2. Due to these limitations, the electrophilic fluorination 
method is only commonly used in applications that don’t require a radiotracer with a high 
specific activity. When a higher specific activity product is necessary and electrophilic 
fluorination is the desired synthetic route, other fluorination reagents such as xenon 
difluoride, N-fluorinated amines, amides, and sulfonamides are used.2 Because the source 
of electrophilic fluorine is contained within the reagent itself, instead of within diatomic 
fluorine (where one atom of radioactive fluorine is consumed in the transformation and 
the other half is converted to unusable radioactive fluoride) these reagents are able to 
provide a higher specific activity material. 
The method used to obtain [18F]-fluoride for use in nucleophilic labeling reactions 
(18O(p,n)18F) is similar to the reaction used to produce [18F]F2, except that the product is 
obtained as [18F]HF from an [18O]-H2O target. This solution is then passed through an 
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ion-exchange resin, which traps the [18F]-fluoride. A solution containing K2CO3 and 
kryptofix 2.2.2 (Figure 1.3) is then used to elute radioactive fluoride (as [18F]KF) from 
the ion-exchange resin into a reactor vial. Typically, the reagent is then mixed with 
acetonitrile and subject to azeotropic distillations to remove excess water to prepare a 
highly nucleophilic form of fluoride.2 
 
Figure 1.3 Kryptofix™ 2.2.2 
Nucleophilic methods have been used to radiofluorinate a variety of compounds. 
These no carrier added (nca) nucleophilic methods, in which the cyclotron produced 
[18F]F- is used directly, can result in very high specific activity products ( > 4 x 103 GBq 
μmol-1). Certain challenges are apparent if fluoride is to be used in nucleophile reaction, 
as fluoride is generally considered to be a poor nucleophile. However, fluoride is a 
moderate nucleophile, but only when it is desolvated, so every effort is made to eliminate 
potentially hydrogen bonding impurities (like water) to enhance the rates of reaction. 
Since alkyl fluorides are highly stable compounds, quite aggressive reaction conditions 
can generally be used for SN2 reactions to form alkyl fluorides.  
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Regardless of whether an electrophilic or nucleophilic method of fluorination is 
used, there are certain constraints placed upon the method of synthesizing the radiotracer, 
due to the inherent properties of 18F. The relatively short-half life of 18F makes it 
desirable to minimize the number of post-labeling synthetic transformations as well as the 
length of any necessary purification processes. While many carrier added electrophilic 
fluorination methodologies seem attractive in this regard, they suffer from low selectivity 
during the labeling step, which translates into a low specific activity final product. 
Because high specific activity product is often required in imaging applications, 
radiochemists are often willing to use multistep syntheses and complex protecting group 
strategies so that [18F]-fluoride may be used to generate high specific activity products. 
Some of the most desirable radiotracers contain fluoroarenes. Radiotracers 
incorporated onto electron-poor arenes may be synthesized using classical SNAr reactions 
such as halogen exchange or fluorodenitration reactions. Strategies to prepare 
radiotracers that possess [18F]-fluorinated electron-rich aromatic groups include direct 
fluorination with [18F]F2 or electrophilic reagents derived from [
18F]F2, or, more 
commonly fluorodestannylation. As outlined above, electrophilic methods generally 
provide tracers that have low specific activity. Due to this limitation, a method that is 
fast, high yielding, and highly selective, while affording the ability to radiolabel both 
activated and deactivated substrates using a no carrier added nucleophilic [18F]F- is highly 
desirable. One objective of research in the DiMagno group is to provide a solution to this 
general problem. 
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1.1.4 Typical Aromatic Fluorination Methods 
One very simple and straightforward method of obtaining aryl fluorides is to 
employ a SNAr reaction to displace a leaving group with fluoride. These types of 
reactions often require high boiling solvents and high temperatures, which may not be 
compatible with sensitive functional groups. Also, owing to the miniscule amount of 
[18F]F- present under no carrier added conditions (< 10 ng), a large excess of the desired 
halogenated arene precursor is required to drive the reaction to completion. For 
radiotracer synthesis, the SNAr approach can lead to significant purification problems. 
One of the most well-known reactions used to produce fluoroarenes is the Balz-
Schiemann (Sandmeyer) reaction. In this method, anilines are converted to diazonium 
fluoroborates, which are subsequently converted to aryl fluorides (Scheme 1.1). This 
route has been used to produce several 18F labeled radiotracers, including [18F]-F-DOPA, 
although the RCY suffers as a result of the use of BF4
-, which limits the maximum 
radiochemical yield to only 25% since only one 18F contained within the BF4
- anion is 
transferred to the arene.2 This method is also not tolerant to many acid-labile functional 
or protecting groups that may need to be used in the synthetic strategy, and as a result, 
fluoroborates are not generally used as a radiosynthetic strategy.2 
 
 
Scheme 1.1 Balz-Schiemann reaction. 
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Another method that has been developed to fluorinate electron-rich aromatic 
compounds is based upon palladium-catalyzed cross coupling reaction, a strategy first 
developed by Buchwald (Scheme 1.2). A solution to this long-standing problem was 
noteworthy, because one would expect that the strength of the Pd-F bond would lead to 
relatively high barriers to reductive elimination of Pd0 to form the fluoroarene during the 
last catalytic step. However, this method is most effective when deactivated aromatics are 
the labeling target, as more electron rich compounds require a large excess of the 
fluorination reagent (6 equivalents of CsF), higher temperatures and longer reaction times 
(12 hours). This method suffers from less than perfect regioselectivity, and the toxicity of 
heavy metals is also a concern, as any potential pharmaceutical must remain metal-free, 
which limits its use as a synthetic strategy to obtain 18F radiolabeled drugs.19-23 
 
 
Scheme 1.2 Pd-catalyzed aromatic fluorination. 
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1.1.5 Diaryliodonium Salts as Precursors to Aryl Fluorides 
In organometallic metal chemistry, it is well known that high-valent and/or 
electronegative transition metal ions are more prone to reductive elimination.20 Using 
recent developments in palladium-catalyzed cross coupling reactions as an analogy, it 
was postulated that iodine should behave like a high-valent, highly electronegative 
transition metal ion in reductive elimination reactions. In addition, because the bond 
between fluorine and palladium is stronger than the bond between fluorine and iodine, 
reductive elimination reactions at I(III) centers should occur more readily than reductive 
elimination reactions at Pd(II) centers. Furthermore, Ar2M(X)n complexes usually give 
biaryl compounds upon reductive elimination, whereas Ar2IX compounds generally from 
Ar-I and Ar-F compounds upon reductive elimination. Because of these properties, our 
group has explored reductive elimination reactions from I(III) centers to develop a 
potentially more facile route to fluoroarenes (Figure 1.4). 
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Figure 1.4 Iodine used as a transition metal. 
 
The decomposition of diaryliodonium salts (IUPAC: diaryl-λ3-iodanes) to aryl 
halides is a reaction that has been known for over one hundred years, but only recently 
has this type of chemistry come into the spotlight.88 The current popularity of 
diaryliodonium chemistry in radiochemistry circles is due to the ability of this class of 
salts to rapidly undergo reductive elimination to form aryl fluorides.24-27 This property 
grants them special utility as radiotracer precursors. In most cases, the desired radiotracer 
can be obtained in one “hot” step after the desired diaryliodane is in hand. Developing 
especially high yielding radiolabeling strategies using this particular class of compounds 
is a primary focus of research in the DiMagno group. 
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Scheme 1.3 Common strategies used to synthesize I(III) compounds. 
 
A variety of methods allow one to synthesize iodonium salts from relatively 
simple arenes. However, in order for synthetic methods to be relevant to radiotracer 
synthesis, they must be general, have high functional group tolerance, and be compatible 
with any needed acid-labile protecting groups. (Nucleophilic radiofluorination reactions 
are generally performed with excess base present.) Two common strategies (Scheme 1.3) 
utilize oxidizing agents in the presence of acid, which would disqualify any drug 
containing acid-labile groups from being a candidate for diaryliodonium salt formation. A 
new strategy (Scheme 1.4), derived from the work of Shreeve,89 circumvents this 
limitation by using the mild oxidant Selectfluor™ in the presence of TMS-acetate to give 
the diacetate in high yield under neutral conditions. Importantly, this process leaves acid-
labile protecting groups intact. 
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Scheme 1.4 Different methods used to synthesize I(III) compounds. 
 
There are numerous literature examples describing the preparation of aryl 
fluorides from diaryliodonium salts. It has been suggested that the decomposition of 
diaryl-λ3-iodanes proceeds via an SNAr mechanism, which directs the nucleophilic 
fluoride onto the ipso carbon of the less electron rich arene due to the ability of the 
electron poor ring to stabilize the negative charge that develops in the transition state.87 
Because of this, many diaryliodonium salts employ electron rich arenes such as 4-
iodoanisole and 2-thienyl as the opposing arene.28-30 Because fluorination of 
diaryliodonium salts involves ionic reactants, this reaction was performed exclusively in 
polar media previously. However, work in our laboratory has shown that the use of 
nonpolar solvents, such as benzene or toluene, suppress detrimental side reactions and 
permit aryl fluorides to be prepared in greater yield.  
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With the ability to quickly synthesize a wide variety of diaryliodonium salts in 
high yield, and the capability to quickly and cleanly obtain the corresponding radiotracers 
from these compounds, my focus shifted to expanding the scope of the diaryliodonium 
salt method. In order to arrive at diaryliodonium salt precursors, however, it was 
necessary to develop a more general and selective method to iodinate compounds that 
would be later transformed into radiotracer precursors. 
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CHAPTER TWO 
 
 
 
 
IODINATED COMPOUNDS IN RADIOSYNTHESIS 
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2.1 BACKGROUND 
2.1.1 Aromatic Iodination 
Aryl iodides have become widely recognized as versatile synthetic intermediates, 
owing to iodine’s excellent ability to act as a leaving group. Iodoarenes readily undergo a 
variety of synthetic transformations including metal-catalyzed cross-coupling reactions, 
diaryliodonium salt chemistry, Grignard reactions, as well as classical SNAr type 
chemistry. Because a wide array of transformations are available for aryl iodides, organic 
molecules containing this moiety often serve as vital precursors to highly desirable 
pharmaceuticals. 
The wide array of methods that have been developed for iodoarene synthesis 
serves as evidence that the fabrication of these important pharmaceutical precursors is not 
straightforward, and that the reaction conditions must be carefully tuned to match the 
substrate. This complication arises from the fact that elemental iodine is the weakest 
electrophile of the halogens, and as a result, synthetic routes to aryl iodides often require 
harsh reaction conditions and highly activated reagents. Moreover, iodine is a relatively 
weak electron-withdrawing aryl substituent63 (Hammett σp = 0.18, σm = 0.35, σ+ = 0.14), 
so polyiodination is often a problem when very electron rich substrates or highly 
activated reagents are used. Activated substrates readily undergo electrophilic iodination, 
although often with poor selectivity. However, deactivated arenes are often difficult to 
iodinate, requiring powerful oxidants and long reaction times in concentrated acid. These 
problems limit the accessibility of iodinated intermediates as pharmaceutical precursors. 
To arrive at these versatile iodoarene intermediates from the corresponding 
aromatic compounds, a variety of reagents may be used, including N-iodosuccinimide 
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(NIS), iodine monochloride (ICl), sodium iodide or molecular iodine used in combination 
with a variety of oxidants, bis(pyridine)-iodonium(I) tetrafluroborate (Py2IBF4), and 
silver or mercury salts combined with I2 (Scheme 2.1). Iodoarenes may also be 
synthesized by various substitution reactions from compounds such as aryl amines, aryl 
halides, aryl boronic acids, aryl triflates and aryl silanes.31-61 
 
 
Scheme 2.1 Various reactions used to synthesize aryl iodides. 
 
Recently, a literature review describing various electrophilic aromatic iodination 
procedures was published.64 Despite the range of reagent systems described in the review, 
there remains the need for a versatile, straightforward, and highly selective aromatic 
iodination method. For example, even the iodination of benzene is not straightforward; a 
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wide variety of the methods used failed to produce iodobenzene in quantitative yield 
(Table 1.2). The notable exception was molecular iodine and silver triflate in 
dichloromethane, however, for the purposes of pharmaceutical synthesis, this reaction is 
problematic. 
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Table 2.1 Iodination of benzene. 
 
Entry Reagent Conditions Temp (ºC) Yield (%) Reference 
1 I2, CrO3 AcOH, Ac2O, H2SO4 65 76 65 
2 I2, SPCa AcOH, Ac2O, H2SO4 40 40 66 
3 I2, I2O5 AcOH, H2SO4 60 56 67 
4 I2/KI, PVPb-H2O2 H3PW12O40, (cat.), CH2Cl2 reflux 15-22 68 
5 I2/NaI, Fe(NO3)3•N2O4 CH2Cl2 r.t. 74 69 
6 NaI, Ce(OH)3OOH aq. SDS r.t. 80 70 
7 KI, KBrO3, H+ 60% AcOH/HCl 80 91 71 
8 I2, XeF2 CH2Cl2 r.t. 90 72 
9 I2, Hg(NO3)2 CH2Cl2 r.t. 52 73 
10 I2, AgOTf CH2Cl2 r.t. 100 74 
*Data drawn from from reference 64. 
a SPC = Sodium percarbonate 
b PVP = polyvinylpyrrolidone 
 
The results obtained from the iodination of alkylbenzenes are similarly 
disappointing. Toluene iodination ordinarily yields a mixture of 2- and 4-iodotoluene in 
systems using relatively harsh reaction conditions. Greater than average selectivity can be 
obtained under milder conditions at longer reaction times or in reactions that employ 
metal catalysts such as tungsten or vanadium (Table 1.3). 
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Table 2.2 Iodination of toluene. 
 
Entry Reagent Conditions Temp (ºC) Ratio (o:p) Yield (%) Reference 
1 NaI or KI Oleum 60-120 0:100 76 75 
2 I2, AgOTf CH2Cl2 r.t. 25:75 100 74 
3 I2, Hg(NO3)2 CH2Cl2 r.t. 35:65 92 73 
4 I2, Fe(NO3)3 CH2Cl2a 20 0:100 59 76 
5 I2, Fe(NO3)3•N2O4 CH2Cl2 r.t. 40:60 93 69 
6 NaI, Ce(OH)3OOH aq. SDS r.t. 0:100 87 70 
7 I2, H5IO6 EtOH 60 8:92 44 77 
8 I2, F-TEDA-BF4 [bmim][PF6] 80 35:65 40 78 
9 I2, O2 MeCNb 80 15:85 99 79 
*Data drawn from from reference 64. 
a Catalytic H3PW12O40 
b H5PV2Mo10O40 
 
 In cases where the iodination of polysubstituted alkylbenzene derivatives was 
attempted, regioisomers and multiple iodination were observed in all but the most 
specific cases. This lack of selectivity is especially troublesome when attempting to 
iodinate compounds for which the sums of the substituent Hammett sigma values are 
similar. Furthermore, because the iodine substituent is not particularly deactivating, 
compounds that have already undergone iodination are susceptible to further iodination. 
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Scheme 2.2 Sandmeyer synthesis of iodoarenes. 
 
Iodination of relatively electron-poor arenes is a difficult task, conventionally 
accomplished by the indirect approach using the Sandmeyer reaction80-82 (Scheme 1.6). 
The alternatives to the Sandmeyer reaction discussed within this section commonly 
employ harsh reaction conditions, use a large excess of the iodination reagent, 
concentrated acid, high temperatures and long reaction times, and/or strong oxidants in 
order to complete the transformation.84-86 Under these conditions, it is difficult to prevent 
multiple iodination, especially if there are two nearly equivalent positions at which 
iodination may occur. In addition, these harsh reaction conditions are often not 
compatible with functional or protective groups that may be necessary for the synthesis 
of complex pharmaceutical candidates. 
 
2.1.2  Aromatic Iodination via Diaryliodonium Salt Decomposition 
Because of the difficulty encountered during the iodination of both electron-rich 
and electron-poor aromatics, we sought a new method that would be selective and robust 
enough that the method could be used to iodinate a wide variety of aromatic substrates. In 
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order to solve this problem, we turned our attention once again to diaryliodonium 
chemistry.  
In order to iodinate any given compound using iodane chemistry, the compound 
in question must first necessarily be transformed into the corresponding diaryliodonium 
salt. This procedure is not trivial, and introduces one or more additional steps into the 
reaction sequence. Typical procedures for preparing diaryliodonium salts involve 
electrophilic and nucleophilic partners, which condense to form the diaryliodonium salt. 
Naturally, this rather complex approach would require an arene already functionalized in 
the appropriate position, and would be a nonsensical method to prepare standard iodides. 
One such approach is shown in (Scheme 1.7). 
 
 
Scheme 2.3 Synthesis of diaryliodonium salts. 
 
A second issue is that the thermal decomposition of diaryliodonium salts leads to 
the formation of two different iodides (if X = I in Figure 1.5), thus there could be a 
separations problem if the two iodoarenes  are chemically similar. 
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Figure 2.1 Products resulting from the reductive elimination of a diaryliodonium salt. 
 
In summary, there are two main problems encountered when attempting to use 
iodane chemistry to introduce iodine into a pharmaceutical precursor. First, the typical 
methods used to obtain the necessary diaryliodonium salts employ precursors that could 
provide the aryl iodides directly; and second, the decomposition of the resulting 
iodonium salt step may give a mixture of products, which could require further costly and 
time-consuming purification steps.83-84 In the following section, I present a fairly general 
solution to the arene iodination problem, and show that it can be applied to a wide range 
of substrates. 
 
2.2 RESULTS AND DISCUSSION 
Portions of the rest of this section are drawn from a journal article on which I am 
a coauthor. Direct quotations are indicated with quotation marks. I have clearly attributed 
individual contributions. 
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In order to overcome the problems outlined previously, I developed a selective 
iodination methodology that can be used to functionalize a variety of electronically 
deactivated to activated arenes. 
In order to address the problem of multiple iodine additions for compounds that 
contain several positions susceptible to electrophilic aromatic substitution, we developed 
a strategy that exploits a fundamental property of I(III) chemistry: the aryliodonium 
substituent is very electron withdrawing (σp = 1.37, σm = 1.35 for PhI(BF4). To put this in 
context, the corresponding values for the nitro substituent are: σp = 0.79, σm = 0.71. Thus, 
any method that involves electrophilic substitution to form an Ar-I(III) intermediate 
effectively eliminates the possibility of any further electrophilic substitution by an “I+” 
species (Scheme 1.8) 
 
 
Scheme 2.4 Resistance of diaryliodonium salts to further EAS 
 
With this strategy in hand, I turned my attention toward developing a direct 
electrophilic substitution method that could be used with a variety of arenes. With my 
attention focused on developing a “one step addition” route to diaryliodonium salts, I 
envisioned a diacetoxyiodoarene that would be sufficiently electron-poor so that the I(III) 
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moiety would readily undergo electrophilic aromatic substitution with the desired 
substrates. To this end, I devised two reagents containing substituents of a sufficiently 
electron-withdrawing nature to facilitate the EAS reaction between arenes and the I(III) 
center of a diacetoxyiodoarene (Scheme 1.9). 
 
  
Scheme 2.5 Reagents used for “One Step Addition” 
 
Reagent 1 ((4-nitrophenyl)iodonium diacetate) and reagent 2 ((3,5-
dicarboxymethylphenyl)iodonium diacetate), were obtained in good yield by treating the 
corresponding iodides with 1.3 equivalents of Selectfluor™ and 2.6 equivalents of 
TMSOAc in acetonitrile (Scheme 1.10). These compounds are stable materials, and they 
are unreactive toward standard arenes in acetonitrile at room temperature. 
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Scheme 2.6 Synthesis of aryliodonium diacetates 
 
Upon electrophilic activation of 1 or 2 with trimethylsilyl triflate (TMSOTf), 
ligand exchange occurs and several different I(III) species (ArI(OAc)2, ArI(OAc)(OTf), 
and ArI(OTf)2) are observed. The evidence for this equilibration can be seen in the 
downfield shifts of signals in the aromatic region of  the 1H NMR spectrum, and by a 
signal consistent with generation of TMSOAc. The greater electrophilicity of the I(III) 
center, which is suggested by the downfield shifts of the signals in the 1H NMR spectrum 
following treatment of ArI(OAc)2 with TMSOTf, was confirmed when an arene such as 
toluene was added; the activated reagents participated in an EAS reaction to give the 
corresponding diaryliodonium salt at room temperature (Scheme 2.7). 
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Scheme 2.7 Activation of the aryliodination reagent and reaction with toluene. 
 
With the diaryliodonium triflate in hand, the corresponding aryl iodide can be 
formed quickly and simply by treatment with tetramethylammonium iodide (TMAI) and 
heating (Scheme 2.8). 
 
 
Scheme 2.8 Conversion of the diaryliodonium triflate to the iodoarene. 
 
In order to determine the general scope of the reaction, I performed a comparison 
between traditional iodination strategies employing the use of N-iodosuccinimide (NIS) 
and Selectfluor™ and our methodology, which employs an I(III) substituted arene. For 
Method A and B, one and two equivalents of NIS were used to assess the selectivity and 
to attempt to drive the reaction to completion, respectively. Likewise, for Method C and 
D, one half and one equivalent of Selectfluor™ and I2 were used for similar purposes. 
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For Method E, two equivalents of the aryliodination reagent 1 or 2 and four 
equivalents of trimethylsilyl triflate (TMSOTf) were used to ensure that all of the arene 
was consumed, and to ensure that multiple iodination did not occur. Because this was a 
preliminary survey of reactivity and scope, and because the decomposition of 
diaryliodonium salts is a thoroughly investigated topic and has been known for over a 
century, the yields listed column E refer only to the yields of the diaryliodonium salt 
intermediate. Even so, the results shown in Table 1.4 indicate that for a wide range of 
substrates, the aryliodination strategy promises to be superior in many regards.  
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Table 2.3. Comparison between standard iodination strategies and the diaryliodination 
strategy. For column E, I = I(OTf)(Ph(NO2)). 
Entry Reactant Product(s) 
Method & Yielda,b (%) 
A B C D Ec 
1 
 
3 
 
78.1 79.7 69.4 26.7 >99c 
 
0 0 16.0 57.2 0 
 
0 0 4.2 16.1 0 
2 
 
4 
 
63.7 100 100 50.7 >99c 
 
0 0 0 49.7 0 
3 
 
5 
 
100 43.0 95.8 3.4 >99c 
 
0 57.0 1.6 96.6 0 
4 
 
6  
100 100 100 100 >99 
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Entry Reactant Product(s) 
Method & Yielda,b (%) 
A B C D Ec 
5 
 
7 
 
- 62.0 85.1 0 >99 
 
- 38.0 14.9 100 0 
6 
 
8  
80.6 100 100 100 >99 
7 
 
9 
 
23.6 36.3 65.2 77.8 >99 
 
4.1 5.6 6.5 21.4 0 
8 
 
10 
 
74.6 74.5 64.1 9.7 88 
 
16.4 12.4 13.4 0 12 
 
0 10.2 17.6 74.6 0 
 
0 2.9 4.9 15.7 0 
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Entry Reactant Product(s) 
Method & Yielda,b (%) 
A B C D Ec 
9 
 
11  
22.5 35.3 76.1 84.3 >99 
10 
 
12  
30.8 55.2 76.9 100 >99 
12 
 
13  
34.6 88.5 88.0 94.5  
11 
 
14 
 
19.9 23.2 41.2 45.0 90c 
 
21.5 20.9 44.5 48.6 10 
 
0 0 0 6.3 0 
12 
 
15 
 
64.1 82.1 90.7 45.1 >99c 
 
1.3 2.5 7.3 51.0 0 
 
0 0 1.8 3.8 0 
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Entry Reactant Product(s) 
Method & Yielda,b (%) 
A B C D Ec 
13 
 
16  
24.8 19.8 66.6 81 >99 
aYield determined by 1H NMR, Full descriptions of methods A-F can be found in Appendix X 
bMethod A: 1.1 eq. NIS/TFA 
 Method B: 2.2 eq. NIS/TFA 
 Method C: 0.5 eq. Selectfluor™/I2 
 Method D: 1.1 eq. Selectfluor™/I2 
 Method E: 2.0 eq. 1 (Nitrophenyliodonium diacetate) & 4.0 eq TMSOTf 
 Method E: 2.0 eq. 2 (3,5-dicarboxymethyl)phenyliodonium diacetate & 4.0 eq TMSOTf 
 cYield of diaryliodonium salt intermediate 
 
 
For all of the alkyl substituted benzenes except toluene and 3-bromoanisole, the 
aryliodination strategy proceeded to 100% conversion within a 2 hours, and produced 
only a single regioisomer, while the N-iodosuccinimide and Selectfluor™ iodination 
method required overnight heating, and gave multiple regioisomers or multiply iodinated 
products. 
Of special note is the comparison of the iodination of p-xylene. When treated with 
one equivalent of N-iodosuccinimide, only 64% of the monoiodination product was 
observed, accompanied by 1.5% of the doubly iodinated product. When subjected to 2 
equivalents of N-iodosuccinimide, the reaction did not proceed to completion, but yielded 
only 82% of the desired mono-iodinated product, while also giving nearly 3% of the 
doubly-iodinated product. However, when p-xylene was treated with 2 equivalents of the 
aryliodination reagent 2, the reaction proceeded to completion within one hour at room 
temperature, and gave the desired product in 99% yield. Similar results are observed for a 
wide range of molecules. 
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The aryliodination was also shown to be applicable to substrates ranging from 
benzaldehydes (electronically deactivated) to anilines (highly activated). In all cases 
where the aryliodination reagent was used, the starting material was completely 
consumed, regardless of electron-rich or poorness. This wide range of reactivity makes 
this iodination strategy particularly attractive as a robust, highly versatile alternative to 
other methods. 
However, there are several drawbacks to the aryliodination approach. “The 
presence of free N-H bonds and phenolic hydroxyl groups were incompatible with the 
aryliodination reaction, although simple protecting group strategies should provide a 
workaround to this problem. Importantly, the presence of hydrogen bonding groups in the 
absence of a reducing functional group is tolerated. Highly reducing arenes (1,4-
dimethylaminobenzene, 1,4-dimethoxybenzene) participated in redox reactions rather 
than EAS, indicating that reduction of the aryliodonium salt was the principal side 
reaction that limits the utility of this method.” For the iodination of particularly electron-
rich aromatics, it is probable that a less activated aryliodonium reagent may be used. In 
these cases, it is likely that the reaction may be modified to suit these electron-rich 
substrates by simply using less potent activator such as trimethylsilyl trifluoroacetate 
(TMSTFA) or similar TMS-X reagent. 
In order to determine the optimal conditions for the reaction, Bao Hu, a 
postdoctoral fellow in the DiMagno laboratory, surveyed the amounts of the 
aryliodination reagent and TMSOTf needed to generate the active electrophile in 
deuterated acetonitrile (CD3CN). The activated aryliodonium species, prepared under a 
variety of conditions, was treated with one equivalent of toluene at room temperature. 
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Under the optimized conditions (Table 1.4), conversion of arene to the diaryliodonium 
salt was complete within one hour. Subsequent treatment with an excess (3 equivalents) 
of sodium iodide and heat (80º C) was sufficient to convert the diaryliodonium salt to the 
corresponding aryl iodides. Excess iodide was used for two reasons: it pushes the 
equilibrium for the intermediate diaryliodonium triflate to the iodide, and it also 
eliminates any unreacted ArIX2 reagent remaining upon completion of the reaction by 
reduction (2I-  I2). 
 
Table 2.4 Optimization conditions for aryliodination 
 
Entry Reagent Ratiob t (h) conv. (%)c 
Iodide 
source 
eq. T (°C) t (h) conv. (%)d 
1 1 1.0/1.5/1.5 1 66 – – – – – 
2 1 1.0/1.5/1.5 8 98 TMAI 2.0 80 13 68 
3 1 1.0/2.0/4.0 0.5 95 – – – – – 
4 1 1.0/2.0/4.0 1 >99 TMAI 2.0 120 1 46 
5 1 1.0/1.5/3.0 1 >99 TMAI 2.0 120 1 71 
6 1 1.0/1.5/3.0 1 >99 TMAI 2.0 120 4 95 
7 1 1.0/1.5/3.0 1 >99 TMAI 4.0 80 1 >99 
8 1 1.0/1.5/3.0 1 >99 TMAI 3.0 80 1 >99 
 38 
91b 1 1.0/1.5/3.0 1 >99 TBAI 3.0 80 1 >99 
10 1 1.0/1.5/3.0 1 >99 NaI 3.0 80 1 >99 (>95)e 
11 2 1.0/1.5/1.5 1 30 – – – – – 
12 2 1.0/1.5/1.5 29 97 – – – – – 
13 2 1.0/1.5/3.0 1 >99 NaI 3.0 120 22 >99 (>95)e 
aReaction conditions: 0.10 mmol scale, 1.5 mL of CD3CN, N2. 
bToluene/1 (or 2)/TMSOTf. 
cBased on toluene. dBased on 4. 
eYields were determined by 1H NMR spectroscopy. 
 
 
The mild (room temperature, no strong oxidant or protic acid) conditions under 
which this reaction takes place suggest that the I(III) electrophile is quite potent, yet the 
reaction proceeds with good regioselectivity. The 9:1 ratio of 4-iodotoluene to 2-
iodotoluene indicates that the regioselectivity observed in the original diaryliodonium salt 
formation is carried through to the products during the decomposition step. 
With the optimized reaction conditions in hand, Dr. Hu sought to further illustrate 
the benefits of using the diaryliodonium method of iodination in comparison to more 
common procedures. As a starting point, and because the aryliodination methodology 
proceeds quite mildly at room temperature, several common iodination strategies were 
performed on toluene at room temperature. These results are shown in Scheme 1.12. 
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Scheme 2.9 Comparison of toluene iodination. 
 
Dr. Hu also performed a survey of the scope of the reaction for the decomposition 
of the diaryliodonium intermediate. For most of the arenes surveyed, the reaction 
proceeded to more than 99% conversion to the diaryliodonium intermediate within one 
hour at room temperature when 1.5 equivalents of the aryliodination reagent (1 or 2) and 
3 equivalents of TMSOTf were used. The diaryliodonium intermediate was converted 
rapidly (within 1 hour) to the corresponding iodide when treated with 3 equivalents of 
sodium iodide in acetonitrile at 80º C. These results are compiled in Table 1.6. In no case 
were multiply iodinated products observed. 
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Table 2.5 Survey of the scope of the aryliodination reaction. 
 
Entry Arene Product Yield (%)b 
1 
  
86c 
2 
 
 
75d 
3 
 
 
78 
98e 
84e,f 
4 
  
93 
5 
  
>95 
6 
  
79 
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Entry Arene Product Yield (%)b 
7 
  
>95 
8 
  
84g 
9 
  
>95g 
>95e,g,h 
81e,g,h,i 
aReaction conditions: 0.10 mmol scale, arene/1/TMSOTf/NaI = 1:1.5:1.5:3.0, 1.5 mL of CD3CN, N2. 
 For details of operation, see the Supporting Information. 
bDetermined by 1H NMR using an internal std. 
cThe iodination required 80 °C for 2 h. 
dThe iodination required 120 °C for 1 h. 
e2 was instead of 1. 
f1 mmol scale. 
gThe oxidation required 1 d. 
h The iodination required 120 °C for 40 min. 
i6 mmol scale. 
 
In order to demonstrate the utility of using this method in a synthetic strategy, I 
attempted to iodinate methyl 2-(4-isobutylphenyl)propanoate, also known as ibuprofen. 
Remarkably, this common material had not been selectively iodinated previously. It is 
difficult to selectively iodinate the methyl ester of ibuprofen, as the 2 and 3 positon on 
the aromatic ring are very electronically similar, and conventional electrophilic aromatic 
substitution methods give a mixture of the two possible regioisomers, which are 
especially difficult to separate using normal phase silica gel chromatography. 
When the ibuprofen methyl ester was subjected to the standard conditions for 
aryliodination using our method, a 9:1 mixture of the two possible regioisomeric 
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diaryliodonium products were obtained (Scheme 1.14). Recrystallization gave the 
desired, regioisomerically pure diaryliodonium salt intermediate product in good yield. 
Dr. Hu then treated the diaryliodonium salt intermediate with 3 equivalents of sodium 
iodide in acetonitrile at 80º C to form the corresponding iodide. Silica gel 
chromatography (1:40 EtOAc:Hexanes) removed 5-iodoisophthalate to provide methyl 2-
(3-iodo-4-isobutylphenyl)propanoate in 65% overall yield. 
 
 
Scheme 2.10 Iodination of ibuprofen methyl ester 
 
Additionally, I attempted to iodinate bisphenol A dimethyl ether (BPAD) using 
this new diaryliodonium salt approach. Initial experiments indicated that the strategy was 
indeed viable, but reagents 1 and 2, when combined with TMSOTf as the activator, 
proved to be overly electrophilic reagents, and reduction of the aryliodonium triflate was 
a predominant side reaction. Dr. Hu, however, was able to use the aryliodination method 
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to produce monoiodinated BPAD in good yield. He used a less aggressive aryliodonation 
reagent, (4-methoxypheny)iodonium diacetate in place of  1 or 2, to form product in good 
yield, as is shown in Scheme 1.14. 
 
 
Scheme 2.11 Iodination of bisphenol A dimethyl ether (BPAD) 
 
The iodination of BPAD is especially remarkable; every other common iodination 
methods that we explored (NIS/TFA, Ag2SO4/I2, ICl) gave inseparable mixtures of 
starting material and singly and multiply iodinated BPAD, even when a large excess of 
BPAD was used. However, aryliodination was capable of forming a single 
diaryliodonium salt, even when only a slight excess of BPAD was used. More surprising 
is that this non-statistical preference for mono-substitution seems to be originate from a 
through-bond electronic effect, since the T-shaped structure of the diaryliodonium salt 
intermediate seems to preclude any through space aryl-aryl interaction of the 4-
methoxyphenyl ring with the unsubstituted ring of BPAD. The singly-substituted 
diaryliodonium salt was readily separated from the unreacted BPAD by precipitation 
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from ethyl acetate with hexanes, and iodination with excess KI was performed in 
excellent yield. 
 
 
 
2.3 CONCLUSIONS 
In comparison to the Sandmeyer reaction, the preparation of aryl iodides using 
aryliodination is functionally simpler and retains many of the advantages of the 
Sandmeyer reaction. The formation of a polar, diaryliodonium salt intermediate that is 
readily purified makes it quite simple to obtain good yields of single regioisomer aryl 
iodides. In addition, the diaryliodonium salt intermediate possesses solubility 
characteristics that make it possible to obtain good yields of iodinated arenes when the 
reaction is carried out at low conversion. The aryliodination reagents’ reactivity may also 
be tuned to match a range of electron-rich arenes, and the polarity of the aryliodoination 
reagents can be modified to simplify product isolation by silica gel chromatography. 
Using this method, iodoarenes that cannot normally be synthesized regioselectively by 
electrophilic aromatic substitution may now be prepared. The two step process  also 
provides a method to  isolate iodoarenes that would otherwise be extremely challenging 
to separate from their unsubstituted parent compounds. Finally, these reagents are 
characterized by a unique combination of reactivity and selectivity—they are 
simultaneously more aggressive, regioselective, and chemoselective than standard 
reagents for electrophilic aromatic iodination.  
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2.4 EXPERIMENTAL 
2.4.1 Materials 
The chemicals were obtained from Aldrich Chemical Company and used as 
received unless otherwise noted. Acetonitrile and acetonitrile-d3 (Cambridge Isotope 
Laboratories) were dried over P2O5, distilled under reduced pressure into flame-dried 
storage tubes, and stored under dry nitrogen. TMSOTf (trimethylsilyl 
trifluoromethanesulfonate) was distilled prior to use. Selectfluor™ (1-chloromethyl-4-
fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)) (Oakwood Chemical 
Company) was dried in vacuo for 2 days at room temperature before use. All other 
reagents were used as received. 1H NMR spectra were recorded on a Bruker Avance 400 
MHz NMR spectrometer in the NMR Laboratory at the University of Nebraska-Lincoln. 
2.4.2 Synthetic Procedures  
Synthesis of 1-(diacetoxyiodo)-4-nitrobenzene, 1 
 
To a 500 mL oven dried Schlenk flask in a nitrogen charged glovebox was added dry 
acetonitrile (250 mL), 1-iodo-4-nitrobenzene (0.08 mol, 19.92 g), 1-(chloromethyl)-4-
fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (0.104 mol, 36.84 g) and 
trimethylsilyl acetate (0.208 mol, 27.50 g). The reaction vessel was sealed, removed from 
the glovebox, and heated at 50 °C for 24 hours with stirring. The reaction was allowed to 
cool to room temperature and the acetonitrile was removed in vacuo. The orange solid 
 51 
was dissolved in dichloromethane (250 mL) washed with pH 5 acetate buffer (3 x 100 
mL), dried over sodium sulfate, filtered, and the solvent was removed by rotary 
evaporation. The orange solid was dissolved in dichloromethane (50 mL), and triturated 
with a 10% diethyl ether/hexanes solution (250 mL) to give a pale yellow solid after 
filtration. The solid was dried at room temperature in vacuo for 24 hours to obtain the 
product in in 85% yield. 1H NMR (CD3CN, 400 MHz, 25 °C): δ 8.337 (q, J = 7.97 Hz, 
4H), 1.949 (s, 6H).  
Synthesis of dimethyl isophthalate 
 
To a 500 mL round bottom flask was added methanol (250 mL) and isophthaloyl 
dichloride (0.1 mol, 20.30 g). The reaction mixture was heated at reflux for 3 hours, 
cooled to 0 °C, and filtered to afford dimethyl isophthalate as a white solid in 96% yield.  
Synthesis of dimethyl 5-iodoisophthalate 
 
To a 96% sulfuric acid solution was added iodine (0.056 mol, 7.11 g) and sodium 
periodate (0.019 mol, 4.06 g). The reaction mixture was heated at 30 °C for 45 minutes, 
at which point the reaction mixture became dark purple and dimethyl isophthalate (0.075 
mol, 14.56 g) was added. After heating for another 12 hours at 30 °C, The reaction 
mixture was poured over crushed ice, neutralized with sodium bicarbonate, filtered, and 
rinsed with water. The purple solid was then dissolved in dichloromethane (100 mL), 
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washed with a saturated sodium bicarbonate solution (1x 100 mL), water (3 x 100 mL), 
and a saturated sodium bisulfite solution (3x 50 mL). The organic layer was dried over 
sodium sulfate and concentrated in vacuo. The resulting white solid was then 
recrystallized from boiling methanol to afford dimethyl 5-iodoisophthalate as a white 
solid. The solid was dried at room temperature in vacuo for 24 hours to obtain the 
product in in 73% yield. 1H NMR (CDCl3, 400 MHz, 25 °C): δ 8.634 (s, 1H), 8.5505 (d, J 
= 1.87 Hz, 2H), 3.957 (s, 6H).  
Synthesis of 1-(diacetoxyiodo)-3,5-dicarboxymethylbenzene, 2 
 
To a 500 mL oven dried Schlenk flask in a nitrogen charged glovebox was added dry 
acetonitrile (250 mL), 5-iodoisophthalate (0.02 mol, 8.76 g), 1-(chloromethyl)-4-fluoro-
1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (0.026 mol, 9.21 g) and 
trimethylsilyl acetate (0.052 mol, 6.88 g). The reaction vessel was sealed, removed from 
the glovebox, and heated at 50 °C for 24 hours with stirring. The reaction was allowed to 
cool to room temperature and the acetonitrile was removed in vacuo. The white solid was 
dissolved in dichloromethane (250 mL) washed with pH = 5 acetate buffer (3 x 100 mL), 
dried over sodium sulfate, and concentrated in vacuo. The orange solid was dissolved in 
dichloromethane (50 mL), and triturated with a 10% diethyl ether/hexanes solution (250 
mL) to give a white solid after filtration. The solid was dried at room temperature in 
vacuo for 24 hours to obtain the product in 80% yield. 1H NMR (CDCl3, 400 MHz, 25 
°C): δ 8.898 (d, J = 1.76 Hz, 2H), 8.866 (d, J = 1.79 Hz, 1H), 4.010 (s, 6H), 2.024 (s, 6H).  
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Method A: Synthesis of iodoarenes using NIS and TFA (1 equivalent) 
A solution of arene (0.1 mmol) in dry acetonitrile-d3 (0.5 mL) was prepared. To 
this mixture was added a solution of 1-iodo-2,5-pyrrolidinedione (N-iodosuccinimide) 
and 2,2,2-trifluoroacetic acid in dry acetonitrile-d3 (1 mL, 1.1 M each in NIS and TFA). 
The reaction vial was sealed and heated at 50 °C for 12 hours. Yields of iodinated arenes 
were determined by 1H NMR spectroscopy. 
Method B: Synthesis of iodoarenes using NIS and TFA (2 equivalents) 
A solution of arene (0.1 mmol) in dry acetonitrile-d3 (0.5 mL) was prepared. To 
this mixture was added a solution of N-iodosuccinimide and 2,2,2-trifluoroacetic acid in 
dry acetonitrile-d3 (1 mL, 2.1 M each in NIS and TFA). The reaction vial was sealed and 
heated at 50 °C for 12 hours. Yields of iodinated arenes were determined by 1H NMR 
spectroscopy. 
Method C: Synthesis of iodoarenes using Selectfluor™ and I2  (1 equivalent) 
To a solution of arene (0.1 mmol) in dry acetonitrile-d3 (0.5 mL) was added 1-
(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (0.06 
mmol, 22 mg). To this mixture was added a solution of iodine in dry acetonitrile-d3 (1 
mL, 0.6 M). The reaction vial was sealed and heated at 50 °C for 12 hours. Yields of 
iodinated arenes were determined by 1H NMR spectroscopy. 
Method D: Synthesis of iodoarenes using Selectfluor™ and I2 (2 equivalents) 
To a solution of arene (0.1 mmol) in dry acetonitrile-d3 (0.5 mL) was added 1-
(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (0.11 
mmol, 39 mg). To this mixture was added an iodine solution in dry acetonitrile-d3 (1 mL, 
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1.1 M). The reaction vial was sealed and heated at 50 °C for 12 hours. Yields of iodinated 
arenes were determined by 1H NMR spectroscopy. 
Method E: Synthesis of iodoarenes using 1-(diacetoxyiodo)-4-nitrobenzene (2 
equivalents) 
In a glovebox under nitrogen, trimethylsilyl trifluoromethanesulfonate (0.4 mmol, 
89 mg) was added to a solution of 1-(diacetoxyiodo)-4-nitrobenzene (0.2 mmol, 73 mg) 
in dry acetonitrile-d3 (1 mL). The solution was transferred to a 5 mm NMR tube, fitted 
with a rubber septum, removed from the glovebox and sealed with paraffin film. To the 
sealed NMR tube was added a solution of arene (0.1 mmol) dissolved in dry acetonitrile-
d3 (0.5 mL). The reaction mixture was kept at room temperature for 3 hours, then 
tetrabutylammonium iodide (0.15 mmol, 56 mg) was added and the reaction mixture was 
diluted with 50 mL dichloromethane. The organic layer was washed with water (3 x 50 
mL), dried over sodium sulfate, and concentrated in vacuo. 
Method F: Synthesis of iodoarenes using 1-(diacetoxyiodo)-3,5-
dicarboxymethylbenzene (2 eqivalents) 
In a glovebox under nitrogen, trimethylsilyl trifluoromethanesulfonate (0.4 mmol, 
89 mg) was added to a solution of dimethyl 1-(diacetoxyiodo)-3,5-
dicarboxymethylbenzene (0.2 mmol, 88 mg) in dry acetonitrile-d3 (1 mL). The solution 
was transferred to a 5 mm NMR tube, fitted with a rubber septum, removed from the 
glovebox and sealed with paraffin film. To the sealed NMR tube was added a solution of 
arene (0.1 mmol) dissolved in dry acetonitrile-d3 (0.5 mL). The reaction mixture was kept 
at room temperature for 3 hours, then tetrabutylammonium iodide (0.15 mmol, 56 mg) 
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was added and the reaction mixture was diluted with 20 mL dichloromethane. The 
organic layer was washed with water (3 x 10 mL), dried over sodium sulfate, and 
concentrated in vacuo. 
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4.1  APPENDIX A: NMR Data 
 
Figure S1. 1H NMR spectrum of 1 in CD3CN.  
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Figure S2. 1H NMR spectrum of 5-iododimethylisophthalate in CDCl3   
 58 
 
Figure S3. 1H NMR spectrum of 2 in CD3CN.   
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Figure S4. 1H NMR spectrum of 3 in CD3CN. 
  
3
 60 
Figure S5. 1H NMR spectrum of the iodination of 3 by Method A in CD3CN. 
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Figure S6. 1H NMR spectrum of the iodination of 3 by Method B in CD3CN. 
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Figure S7. 1H NMR spectrum of the iodination of 3 by Method C in CD3CN. 
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Figure S8. 1H NMR spectrum of the iodination of 3 by Method D in CD3CN. 
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Figure S9. 1H NMR spectrum of the iodination of 3 by Method F in CD3CN. 
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Figure S11. 1H NMR spectrum of 4 in CD3CN. 
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Figure S12. 1H NMR spectrum of the iodination of 4 by Method A in CD3CN. 
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Figure S13. 1H NMR spectrum of the iodination of 4 by Method B in CD3CN. 
  
4
 68 
 
Figure S14. 1H NMR spectrum of the iodination of 4 by Method C in CD3CN. 
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Figure S15. 1H NMR spectrum of the iodination of 4 by Method D in CD3CN. 
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Figure S16. 1H NMR spectrum of the iodination of 4 by Method F in CD3CN. 
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Figure S17. 1H NMR spectrum of 5 in CD3CN. 
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Figure S18. 1H NMR spectrum of the iodination of 5 by Method A in CD3CN. 
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Figure S19. 1H NMR spectrum of the iodination of 5 by Method B in CD3CN. 
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Figure S20. 1H NMR spectrum of the iodination of 5 by Method C in CD3CN. 
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Figure S21. 1H NMR spectrum of the iodination of 5 by Method D in CD3CN. 
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Figure S22. 1H NMR spectrum of the iodination of 5 by Method f in CD3CN. 
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Figure S23. 1H NMR spectrum of 6 in CD3CN. 
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Figure S24. 1H NMR spectrum of the iodination of 6 by Method A in CD3CN. 
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Figure S25. 1H NMR spectrum of the iodination of 6 by Method B in CD3CN. 
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Figure S26. 1H NMR spectrum of the iodination of 6 by Method C in CD3CN. 
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Figure S27. 1H NMR spectrum of the iodination of 6 by Method D in CD3CN. 
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Figure S28. 1H NMR spectrum of the iodination of 6 by Method E in CD3CN. 
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Figure S29. 1H NMR spectrum of 7 in CD3CN. 
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Figure S31. 1H NMR spectrum of the iodination of 7 by Method B in CD3CN. 
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Figure S32. 1H NMR spectrum of the iodination of 7 by Method C in CD3CN. 
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Figure S33. 1H NMR spectrum of the iodination of 7 by Method D in CD3CN. 
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Figure S34. 1H NMR spectrum of the iodination of 7 by Method E in CD3CN. 
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Figure S35. 1H NMR spectrum of 8 in CD3CN. 
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Figure S36. 1H NMR spectrum of the iodination of 8 by Method A in CD3CN. 
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Figure S37. 1H NMR spectrum of the iodination of 8 by Method B in CD3CN. 
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Figure S38. 1H NMR spectrum of the iodination of 8 by Method C in CD3CN. 
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Figure S39. 1H NMR spectrum of the iodination of 8 by Method D in CD3CN. 
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Figure S40. 1H NMR spectrum of the iodination of 8 by Method E in CD3CN. 
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Figure S53. 1H NMR spectrum of 11 in CD3CN. 
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Figure S54. 1H NMR spectrum of the iodination of 11 by Method A in CD3CN. 
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Figure S55. 1H NMR spectrum of the iodination of 11 by Method B in CD3CN. 
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Figure S56. 1H NMR spectrum of the iodination of 11 by Method C in CD3CN. 
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Figure S57. 1H NMR spectrum of the iodination of 11 by Method D in CD3CN. 
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Figure S58. 1H NMR spectrum of the iodination of 11 by Method E in CD3CN. 
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Figure S59. 1H NMR spectrum of 12 in CD3CN. 
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Figure S60. 1H NMR spectrum of the iodination of 12 by Method A in CD3CN. 
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Figure S61. 1H NMR spectrum of the iodination of 12 by Method B in CD3CN. 
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Figure S62. 1H NMR spectrum of the iodination of 12 by Method C in CD3CN. 
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Figure S63. 1H NMR spectrum of the iodination of 12 by Method D in CD3CN. 
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Figure S64. 1H NMR spectrum of the iodination of 12 by Method E in CD3CN. 
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Figure S65. 1H NMR spectrum of 13 in CD3CN. 
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Figure S66. 1H NMR spectrum of the iodination of 13 by Method A in CD3CN. 
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Figure S67. 1H NMR spectrum of the iodination of 13 by Method B in CD3CN. 
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Figure S68. 1H NMR spectrum of the iodination of 13 by Method C in CD3CN. 
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Figure S69. 1H NMR spectrum of the iodination of 13 by Method D in CD3CN. 
  
 111 
  
Figure S70. 1H NMR spectrum of the iodination of 13 by Method E in CD3CN. 
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Figure S77. 1H NMR spectrum of 15 in CD3CN. 
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Figure S78. 1H NMR spectrum of the iodination of 15 by Method A in CD3CN. 
  
15
 114 
 
Figure S79. 1H NMR spectrum of the iodination of 15 by Method B in CD3CN. 
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Figure S80. 1H NMR spectrum of the iodination of 15 by Method C in CD3CN. 
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Figure S81. 1H NMR spectrum of the iodination of 15 by Method D in CD3CN. 
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Figure S82. 1H NMR spectrum of the iodination of 15 by Method F in CD3CN. 
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Figure S83. 1H NMR spectrum of 16 in CD3CN. 
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Figure S84. 1H NMR spectrum of the iodination of 16 by Method A in CD3CN. 
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Figure S85. 1H NMR spectrum of the iodination of 16 by Method B in CD3CN. 
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Figure S86. 1H NMR spectrum of the iodination of 16 by Method C in CD3CN. 
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Figure S87. 1H NMR spectrum of the iodination of 16 by Method D in CD3CN. 
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Figure S88. 1H NMR spectrum of the iodination of 16 by Method F in CD3CN. 
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Figure S89. 1H NMR spectrum of 17 in CD3CN. 
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Figure S90. 1H NMR spectrum of the iodination of 17 by Method A in CD3CN. 
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Figure S91. 1H NMR spectrum of the iodination of 17 by Method B in CD3CN. 
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Figure S92. 1H NMR spectrum of the iodination of 17 by Method C in CD3CN. 
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Figure S93. 1H NMR spectrum of the iodination of 17 by Method D in CD3CN. 
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Figure S94. 1H NMR spectrum of the iodination of 17 by Method E in CD3CN. 
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Figure S107. 1H NMR spectrum of 20 in CD3CN. 
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Figure S108. 1H NMR spectrum of the iodination of 20 by Method A in CD3CN. 
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Figure S109. 1H NMR spectrum of the iodination of 20 by Method B in CD3CN. 
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Figure S110. 1H NMR spectrum of the iodination of 20 by Method C in CD3CN. 
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Figure S111. 1H NMR spectrum of the iodination of 20 by Method D in CD3CN. 
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Figure S112. 1H NMR spectrum of the iodination of 20 by Method E in CD3CN.
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